课题基金 / 基金详情

Role of the peptidase endothelin-converting enzyme-1 (ECE-1) in neurogenic inflammation, puritus and pain

Role of the peptidase endothelin-converting enzyme-1 (ECE-1) in neurogenic inflammation, puritus and pain
肽酶内皮素转换酶 1 (ECE-1) 在神经源性炎症、瘙痒和疼痛中的作用
批准号:
190198712
负责人:
Dr. Cordula Kempkes
金额:
$0.0万
依托单位:
依托单位国家:
德国
项目类别:
Research Fellowships
财政年份:
2010
资助国家:
德国
项目状态:
已结题
起止时间:
2009-12-31 至 2010-12-31

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The bidirectional communication between skin cells and the peripheral nerve system (PNS) is important for regulatory processes in the skin, as pathophysiological conditions results in skin diseases, atopic dermatitis, urticaria or prurigo, for example. Activation of nociceptive nerve fibers leads to the release of neuropeptides from peripheral nerve endings, which mediate inflammation, itch, and pain by activating their corresponding G protein-coupled receptors (GPCR). For instance, the neuropeptide Substance P (SP) is directly involved in pain and inflammation by activating the neurokinin-1 receptor (NK1R). An important aspect of neuropeptide-mediated function is the interaction of the neuropeptide with its corresponding receptor and the controlling peptidase. Recently we presented the important role of the peptidase endothelin-converting enzyme-1 (ECE-1) for the regulation of certain neuropeptide receptors. This mechanism is not only important for receptor resensitization but also for intracellular signalling pathways (e.g. MAP kinases) in the cell. The aim of my project at the UCSF in San Francisco will be to test if ECE-1 is an important regulator of inflammation, pruritus or pain. Therefore, the aims of my study are 1) to analyze the expression and distribution of ECE-1, SP and NK1R in chronic inflammatory skin diseases, 2) to study the role of ECE-1 and NK1R on cell signalling events that are involved in neurogenic inflammation in vitro, and 3) investigate the role of ECE-1 and neuropeptide receptors in neurogenic inflammation and pain mouse models in vivo.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
II型糖尿病靶标二肽基肽酶IV(DPP-IV)新型抑制剂的设计、合成及药理学研究
  • 批准号:
    30973642
  • 项目类别:
    面上项目
  • 资助金额:
    8.0万元
  • 批准年份:
    2009
  • 负责人:
    刘桂霞
  • 依托单位: